Hello world!

by @JTC_PALIdev | Jul 25, 2024 | Uncategorized

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108

by @JTC_PALIdev | Jul 19, 2024 | Press Releases

Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad claims for “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors” with similar structure to PALI-2108 and PALI-1908 This patent family provides...

Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

by @JTC_PALIdev | Jul 11, 2024 | Press Releases

Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance Company has successfully formulated enteric-coated tablets of PALI-2108 and has demonstrated consistent and reliable drug release profiles Company on track...

Palisade Bio to Participate in the Virtual Investor Closing Bell Series

by @JTC_PALIdev | Jun 24, 2024 | Press Releases

Live video webcast on Wednesday, June 26th at 4:00 PM ET Carlsbad, CA, June 24, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for...

Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences

by @JTC_PALIdev | Jun 21, 2024 | Press Releases

– Collaboration advancing Palisade Bio’s precision medicine approach through access to cutting-edge expertise and tools in bioinformatics – Candidate PDE4-related biomarkers overlapping with UC pathophysiology have been identified and innovative...